Dextromethophan
PreclinicalSmall molecule
Dextromethophan is one of 11 small molecule programs targeting Major Depression. It is currently in Preclinical.
1
Indications
2
Total Trials
1
Active Trials
10
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
14 competitors in Major Depression
#DrugCompanyPhaseTrials
1Prozac
VVitae Pharmaceuticals Inc., an Allergan affiliate
Approved
Psilocybin
COMPASS PathwaysPhase 3
Actemra
CCelltrion
Phase 2
Lexapro
SShirley Ryan AbilityLab
Preclinical
D-Cycloserine
MMassachusetts General Hospital
Preclinical
NRX-101
NNeuroRx, Inc.
Phase 1
SP-624
SSirtsei Pharmaceuticals, Inc.
Phase 1
Ropinirole CR
GSKPreclinical
Choline Alphoscerate
SSamsung Medical Center
Preclinical
Dextromethophan
DDuke University
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Dextromethophan. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- DDuke University